GAGs: glucosaminoglucanos; MPS I: mucopolisacaridosis de tipo I; ORL: otorrinolaringología.

Beck M, et al. Genet Med. 2014;16(10):759-765.
D’Aco K, et al. Eur J Pediatr. 2012;171(6):911-919.
Lehman TJ, et al. Rheumatology. 2011;50(suppl 5):v41-v48.
Giugliani R, et al. Genet Mol Biol. 2010;33(4):589-604.
Soni-Jaiswal A, et al. Orphanet J Rare Dis. 2016;11(1):96.
Cimaz R, et al. Pediatr Rheumatol Online J. 2009;7:18.
Rigoldi M, Verrecchia E, Manna R, et al. Clinical hints to diagnosis of attenuated forms of Mucopolysaccharidoses. Italian Journal of Pediatrics 2018;44(Suppl 2):132.
Gabrielli O, Clarke LA, Ficcadenti A, et al. 12 year follow up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I: the important role of early treatment. BMC Medical Genetics 2016;17:19.
Muenzer J, Wraith JE, Clarke LA. Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics. 2009;123(1):19-29.
Vijay S, Wraith JE. Clinical presentation and follow-up of patients with the attenuated phenotype of mucopolysaccharidosis type I. Acta Paediatr. 2005;94(7):872-877.
Murphy AM, Lambert DM, Treacy EP, O’Meara A, Lynch SA. Incidence and prevalence of mucopolysaccharidosis type 1 in the Irish Republic. Arch Dis Child 2009;94:52-4.
Neufeld EF and Muenzer J. (2001) The mucopolysaccharidoses. In: The Metabolic and Molecular Bases of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, and Vogelstein B. (eds.). 8th edition, Vol. III. McGraw-Hill, Medical Publishing Division, pp. 3421
Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-54.
Moore D, et al. The prevalence of and survival in Mucopolysaccharidosis I: Hurler, Hurler-Scheie and Scheie syndromes in the UK. Orphanet J Rare Dis 2008;3:24.
Lin HY, Lin SP, Chuang CK, et al. Incidence of the mucopolysaccharidoses in Taiwan, 1984-2004. Am J Med Genet A 2009;149A:960-4.
Malm G, Lund AM, Mansson JE, Heiberg A. Mucopolysaccharidoses in the Scandinavian countries: incidence and prevalence. Acta Paediatr 2008;97:1577-81.
Protocole National de Diagnostic et de Soins MPS – HAS – Juillet 2016
Lehman TJA, Miller N, Norquist B et al. Diagnosis of the mucopolysaccharidoses. Rheumatology 2011;50:v41-v18
Johnson BA, Dajnoki A, Bodamer OA. Diagnosing lysosomal storage disorders: mucopolysaccharidosis type I. Curr Protoc Hum Genet. 2015 Jan 20;84:17.17.1-8.
Foster HE, Jandial S. pGALS - paediatric Gait Arms Legs and Spine: a simple examination of the musculoskeletal system. Pediatr Rheumatol Online J 2013;11(1):44
Guffon N, et al. Growth impairment and limited range of joint motion in children should raise suspicion of an attenuated form of mucopolysaccharidosis: expert opinion. Eur J Pediatr 2019;178(4):593–603.
Tylki-Szymańska A, et al. Acta Paediatr. 2018;107(8):1402-1408.

MPS I

Artículos

Opciones de tratamiento y manejo de la MPS I

Diagnóstico y pruebas de la MPS I